|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2001-10-11
|
|
pubmed:abstractText |
Vasoactive intestinal peptide (VIP) is one of several small neuropeptides that affect cancer growth. A lipophilic VIP analog, stearyl-Nle(17)-neuroten-sin(6-11)VIP(7-28) (SNH) that inhibited lung carcinoma growth has been described previously. The experiments performed were clonogenic assays in vitro and tumor xenografts in nude mice in vivo. These studies were now extended to colon carcinoma and to combination therapy with chemotherapeutic agents.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/(VIP-neurotensin) hybrid antagonist,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Growth Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Neurotensin,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Vasoactive Intestinal...,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Vasoactive Intestinal...,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Vasoactive Intestinal...,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Vasoactive Intestinal Peptide,
http://linkedlifedata.com/resource/pubmed/chemical/stearyl-norleucine(17)-vasoactive...
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2001 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
92
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2172-80
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11596035-Animals,
pubmed-meshheading:11596035-Antineoplastic Agents,
pubmed-meshheading:11596035-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:11596035-Drug Synergism,
pubmed-meshheading:11596035-Growth Inhibitors,
pubmed-meshheading:11596035-Humans,
pubmed-meshheading:11596035-Lung Neoplasms,
pubmed-meshheading:11596035-Neurotensin,
pubmed-meshheading:11596035-Receptors, Vasoactive Intestinal Peptide,
pubmed-meshheading:11596035-Receptors, Vasoactive Intestinal Peptide, Type II,
pubmed-meshheading:11596035-Receptors, Vasoactive Intestinal Polypeptide, Type I,
pubmed-meshheading:11596035-Recombinant Fusion Proteins,
pubmed-meshheading:11596035-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:11596035-Tumor Cells, Cultured,
pubmed-meshheading:11596035-Tumor Stem Cell Assay,
pubmed-meshheading:11596035-Vasoactive Intestinal Peptide,
pubmed-meshheading:11596035-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines.
|
|
pubmed:affiliation |
Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
